Telithromycin: The Perils of Hasty Adoption and Persistence of Off-Label Prescribing

Gleason, Patrick P.; Walters, Carol; Heaton, Alan; Schafer, Jeremy A.

doi:10.18553/jmcp.2007.13.5.420

Cited by 34 publications

(20 citation statements)

References 13 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Clarithromycin claims remained consistent during this period. 21 However, our findings differ from those of Wilkinson et al, who found that after 2 FDA warnings, utilization of cisapride and troglitazone continued to increase. 22 It was not until after 5 FDA alerts for cisapride and 4 alerts for troglitazone that utilization of cisapride and troglitazone declined significantly.…”

Section: ■■ Discussioncontrasting

confidence: 99%

Rosiglitazone and Pioglitazone Utilization from January 2007 Through May 2008 Associated With Five Risk-Warning Events

Starner¹,

Schafer²,

Heaton³

et al. 2008

JMCP

Self Cite

View full text Add to dashboard Cite

Section: ■■ Discussioncontrasting

confidence: 99%

Rosiglitazone and Pioglitazone Utilization from January 2007 Through May 2008 Associated With Five Risk-Warning Events

Starner¹,

Schafer²,

Heaton³

et al. 2008

JMCP

Self Cite

View full text Add to dashboard Cite

“…Telithromycin is a ketolide that was designed to overcome the low-(efflux) and high-level (alteration of the 50S ribosomal binding site) macrolide resistance. The appeal of its in vitro potency and once-daily dosing have been diminished by the reports of hepatotoxicity that have resulted in removal of telithromycin's indications for acute sinusitis and acute exacerbations of chronic bronchitis [7]. Telithromycin's use can also be limited by its potent inhibitor of CYP450 3A4 and lack of an intravenous formulation.…”

Section: Macrolides/ketolidementioning

confidence: 99%

Treatment of community-acquired pneumonia

Lee

Houngue

Hall

2015

Expert Review of Anti-infective Therapy

View full text Add to dashboard Cite

Community-acquired pneumonia is the sixth leading cause of death in the USA. Adherence to the 2007 Infectious Diseases Society of America/American Thoracic Society community-acquired pneumonia guidelines has been associated with improved clinical outcomes. However, choice between guideline-recommended treatments is at the discretion of the prescribing clinician. This review is intended to discuss the characteristics of these treatment options including dosing frequency, dose adjustment for renal/hepatic dysfunction, serious/common adverse events, drug interactions, lung penetration, pharmacokinetic-pharmacodynamic target and effect of obesity to help guide antimicrobial selection. An increasing portion of patients are receiving expanded empiric coverage for methicillin-resistant Staphylococcus aureus as recommended by the American Thoracic Society and Infectious Diseases Society of America for healthcare-associated pneumonia. However, this expanded coverage may not be achieving the desired improvements in clinical outcomes. We expect this increasingly diverse spectrum of patients with pneumonia to eventually result in the merger of these two guidelines to include all patients with pneumonia.

show abstract

“…However, after approval of telithromycin, its alarming adverse events were noted, such as hepatotoxicity, myasthenia gravis exacerbation and vision disturbances. Therefore, telithromycin was withdrawn for treating ABECB and acute bacterial sinusitis [40]. Cethromycin (Advanced Life Sciences), another ketolide agent, was shown to target CAP while having a high safety profile.…”

Section: Ketolidesmentioning

confidence: 99%

New perspectives on antibacterial drug research

2013

View full text Add to dashboard Cite

Bacterial resistance to commonly used antibiotics is constantly increasing. Bacteria particularly dangerous for human life are methicillin-resistant Staphylococcus aureus, vancomycin-resistant Enterococcus faecium and fluoroquinolone-resistant Pseudomonas aeruginosa. Hence, there is an incessant need for developing compounds with new modes of action and seeking alternate drug targets. In this review, the authors discuss the current situation of antibacterial medicines and present data on new antibiotic targets. Moreover, alternatives to antibiotics, such as bacteriophages, antimicrobial peptides and monoclonal antibodies, are presented. The authors also draw attention to the valuable features of natural sources in developing antibacterial compounds. The need to prevent and control infections as well as the reasonable use of currently available antibiotics is also emphasized.

show abstract

Telithromycin: The Perils of Hasty Adoption and Persistence of Off-Label Prescribing

Cited by 34 publications

References 13 publications

Rosiglitazone and Pioglitazone Utilization from January 2007 Through May 2008 Associated With Five Risk-Warning Events

Rosiglitazone and Pioglitazone Utilization from January 2007 Through May 2008 Associated With Five Risk-Warning Events

Treatment of community-acquired pneumonia

New perspectives on antibacterial drug research

Contact Info

Product

Resources

About